84 related articles for article (PubMed ID: 8669845)
1. Serum evaluation of basic FGF in breast cancer patients.
Sliutz G; Tempfer C; Obermair A; Dadak C; Kainz C
Anticancer Res; 1995; 15(6B):2675-7. PubMed ID: 8669845
[TBL] [Abstract][Full Text] [Related]
2. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients.
Pichon MF; Moulin G; Pallud C; Pecking A; Floiras JL
Anticancer Res; 2000; 20(2B):1189-94. PubMed ID: 10810420
[TBL] [Abstract][Full Text] [Related]
3. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
4. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
5. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
6. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
7. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
8. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
9. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
Granato AM; Nanni O; Falcini F; Folli S; Mosconi G; De Paola F; Medri L; Amadori D; Volpi A
Breast Cancer Res; 2004; 6(1):R38-45. PubMed ID: 14680499
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients.
Lin RY; Argenta PA; Sullivan KM; Adzick NS
Clin Cancer Res; 1995 Mar; 1(3):327-31. PubMed ID: 9815988
[TBL] [Abstract][Full Text] [Related]
11. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
12. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.
Ruotsalainen T; Joensuu H; Mattson K; Salven P
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1492-5. PubMed ID: 12433733
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
16. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
17. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
18. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
19. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
20. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
